| scholarly article | Q13442814 |
| P356 | DOI | 10.5607/EN.2014.23.1.36 |
| P8608 | Fatcat ID | release_u7ogpne6z5a4bdel4bdxeda6d4 |
| P932 | PMC publication ID | 3984955 |
| P698 | PubMed publication ID | 24737938 |
| P5875 | ResearchGate publication ID | 261745661 |
| P2093 | author name string | Kyong-Tai Kim | |
| Sangjune Kim | |||
| P2860 | cites work | The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription | Q22254119 |
| A huntingtin-associated protein enriched in brain with implications for pathology | Q24303499 | ||
| The selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein Alfy | Q24307759 | ||
| Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity | Q24317318 | ||
| Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series | Q24537164 | ||
| Misfolded proteins partition between two distinct quality control compartments | Q24651093 | ||
| Dual Action of ATP Hydrolysis Couples Lid Closure to Substrate Release into the Group II Chaperonin Chamber | Q27666606 | ||
| Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin | Q27766755 | ||
| Microtubule acetylation promotes kinesin-1 binding and transport. | Q27919704 | ||
| Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1 | Q28118304 | ||
| Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes | Q28189644 | ||
| Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease | Q28202050 | ||
| Normal huntingtin function: an alternative approach to Huntington's disease | Q28281904 | ||
| Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes | Q28302701 | ||
| Regulation of HSF1 function in the heat stress response: implications in aging and disease | Q28307651 | ||
| Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules | Q28590634 | ||
| Trinucleotide Repeat Disorders | Q29038716 | ||
| Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. | Q52573641 | ||
| Dynamic regulation of molecular chaperone gene expression in polyglutamine disease. | Q52659334 | ||
| Proteasome-dependent degradation of cytosolic chaperonin CCT | Q73300148 | ||
| Caspase-8 is required for cell death induced by expanded polyglutamine repeats. | Q40961806 | ||
| Genetic suppression of polyglutamine toxicity in Drosophila | Q41724127 | ||
| The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation | Q42699018 | ||
| Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism | Q43100835 | ||
| Insoluble TATA-binding protein accumulation in Huntington's disease cortex. | Q44280721 | ||
| Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. | Q44286601 | ||
| Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach | Q44872348 | ||
| Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease | Q45298652 | ||
| Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. | Q45300254 | ||
| Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin | Q45301569 | ||
| Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. | Q45302702 | ||
| Systemic administration of Congo red does not improve motor or cognitive function in R6/2 mice. | Q45303103 | ||
| Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease | Q45304607 | ||
| R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice | Q45306743 | ||
| Oligoproline effects on polyglutamine conformation and aggregation | Q46830417 | ||
| Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. | Q50715387 | ||
| Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes | Q30536567 | ||
| Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression | Q31139684 | ||
| Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila | Q31142912 | ||
| Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease | Q33292417 | ||
| Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease | Q33526350 | ||
| The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions | Q33693921 | ||
| Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation | Q33694463 | ||
| Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions | Q33914031 | ||
| Glutamine repeats and neurodegeneration | Q33938576 | ||
| Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. | Q33948101 | ||
| Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease | Q34358457 | ||
| Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? | Q34747079 | ||
| Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease | Q34763178 | ||
| Chaperones and aging: role in neurodegeneration and in other civilizational diseases | Q34815474 | ||
| Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders | Q34952853 | ||
| Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils | Q35169533 | ||
| Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse | Q35345762 | ||
| Protein folding revisited. A polypeptide chain at the folding ? misfolding ? nonfolding cross-roads: which way to go? | Q35549177 | ||
| Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones | Q35674426 | ||
| Modulation of neurodegeneration by molecular chaperones | Q35990274 | ||
| A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse | Q36082278 | ||
| TRiC's tricks inhibit huntingtin aggregation | Q36998752 | ||
| Prefoldin protects neuronal cells from polyglutamine toxicity by preventing aggregation formation | Q37000637 | ||
| Targeting H3K4 trimethylation in Huntington disease | Q37088721 | ||
| Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin | Q37157299 | ||
| Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease | Q37336253 | ||
| Vaccinia-related kinase 2 mediates accumulation of polyglutamine aggregates via negative regulation of the chaperonin TRiC. | Q37546880 | ||
| The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies | Q37570639 | ||
| Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease | Q38345839 | ||
| GRP78 counteracts cell death and protein aggregation caused by mutant huntingtin proteins | Q39366737 | ||
| Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor. | Q40010916 | ||
| Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation | Q40152899 | ||
| Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models | Q40392026 | ||
| Protein quality control: chaperones culling corrupt conformations | Q40400832 | ||
| Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release | Q40551652 | ||
| Purification of polyglutamine aggregates and identification of elongation factor-1alpha and heat shock protein 84 as aggregate-interacting proteins. | Q40692086 | ||
| Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. | Q40704833 | ||
| Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells | Q40886004 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | protein aggregation | Q7251455 |
| Huntington's disease | Q190564 | ||
| P304 | page(s) | 36-44 | |
| P577 | publication date | 2014-03-01 | |
| P1433 | published in | Experimental neurobiology | Q26842060 |
| P1476 | title | Therapeutic Approaches for Inhibition of Protein Aggregation in Huntington's Disease | |
| P478 | volume | 23 |
| Q58608836 | Aggregated SOD1 causes selective death of cultured human motor neurons |
| Q36913723 | Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots. |
| Q91670445 | Brain Microbiota in Huntington's Disease Patients |
| Q38421354 | Car drivers with dementia: Different complications due to different etiologies? |
| Q52350721 | Fractionation for Resolution of Soluble and Insoluble Huntingtin Species. |
| Q45299657 | Hope for Huntington's disease? A novel approach for disease modification |
| Q47133162 | Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets. |
| Q64912813 | Novel targets for Huntington's disease: future prospects. |
| Q26828757 | On the role of 4-hydroxynonenal in health and disease |
| Q56770267 | The role of Twist1 in mutant huntingtin-induced transcriptional alterations and neurotoxicity |
Search more.